Kommentar fra Per Hansen, Investeringsøkonom, Nordnet
Gubra har offentliggjort fase 1 data fra ABBV-295
Fase 1 er 5-6 år væk fra markedet, i givet fald
Vægttab på 7,75-9,79 % er fornuftigt
Ikke mindst fordi det i hovedsagen er mænd, som der er testet på, og erfaringer viser at kvinder taber sig mere
Der er samtidig testet på BMI under 30.
Aktien sendes massivt ned, men data er ikke så dårlige som aktiekursen i dag udtrykker
Gubra har offentliggjort fase 1 data fra ABBV-295
Fase 1 er 5-6 år væk fra markedet, i givet fald
Vægttab på 7,75-9,79 % er fornuftigt
Ikke mindst fordi det i hovedsagen er mænd, som der er testet på, og erfaringer viser at kvinder taber sig mere
Der er samtidig testet på BMI under 30.
Aktien sendes massivt ned, men data er ikke så dårlige som aktiekursen i dag udtrykker
9/3 2026 15:41 ProInvestorNEWS 0
131478 AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
https://finance.yahoo.com/news/abbvie-announces-positive-topline-results-120000040.html?guccounter=1&guce_referrer=aHR0cHM6Ly90LmNvLw&guce_referrer_sig=AQAAANadp33ALtrGqEzqQkREWV4Kr5ubL5cOgoqLrHNdDgyEFTpR2ZwfDjVVhK1cqzuYT3TrUdWlpw4RkezuolpXLTxHSh_-NxFhu53bFkqe9L--klR4z4uH2OdWHGvUsxpJAheRcqtLkeBGQrzsMDKIiZWs40Wtp3qymZzToI-kQDsw
https://finance.yahoo.com/news/abbvie-announces-positive-topline-results-120000040.html?guccounter=1&guce_referrer=aHR0cHM6Ly90LmNvLw&guce_referrer_sig=AQAAANadp33ALtrGqEzqQkREWV4Kr5ubL5cOgoqLrHNdDgyEFTpR2ZwfDjVVhK1cqzuYT3TrUdWlpw4RkezuolpXLTxHSh_-NxFhu53bFkqe9L--klR4z4uH2OdWHGvUsxpJAheRcqtLkeBGQrzsMDKIiZWs40Wtp3qymZzToI-kQDsw
10/3 2026 15:34 bb8 0131487 AbbVie Announces Positive Topline Results from a Phase 1 Multiple Ascending Dose Study of ABBV-295, a Long-Acting Amylin Analog, in Adults
https://news.abbvie.com/2026-03-09-AbbVie-Announces-Positive-Topline-Results-from-a-Phase-1-Multiple-Ascending-Dose-Study-of-ABBV-295,-a-Long-Acting-Amylin-Analog,-in-Adults
"Study enrollment mostly comprised male participants (88.3%)."
A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295
https://clinicaltrials.gov/study/NCT06144684
---
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
https://clinicaltrials.gov/study/NCT07291232
A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives
https://clinicaltrials.gov/study/NCT07414784
https://news.abbvie.com/2026-03-09-AbbVie-Announces-Positive-Topline-Results-from-a-Phase-1-Multiple-Ascending-Dose-Study-of-ABBV-295,-a-Long-Acting-Amylin-Analog,-in-Adults
"Study enrollment mostly comprised male participants (88.3%)."
A Two-Part First-In-Human Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB014295
https://clinicaltrials.gov/study/NCT06144684
---
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
https://clinicaltrials.gov/study/NCT07291232
A Study of ABBV-295 Subcutaneous Injections to Assess Pharmacokinetics and Adverse Events in Healthy Adult Women Participants With Overweight or Obesity Taking Oral Contraceptives
https://clinicaltrials.gov/study/NCT07414784
11/3 2026 12:08 koden 0131490 Jeg skal bare forstå... hvordan kan man være tilfreds med de % når markedet netop fokuserer på netop det? Er de % ikke at sammenligne med Novo og LLY 20+ %?
Er det fordi bivirkninger er færre man kan acceptere 8%?
Er det fordi bivirkninger er færre man kan acceptere 8%?
